CIRM Funded Clinical Trials

Genetic Re-programming of Stem Cells to Fight Cancer

Antoni Ribas
Disease Area: 
CIRM Grant:
DR2A-05309 (Closed)
Award Value:
Trial Stage: 
Phase 1
Trial Status: 
Targeted Enrollment:
12 ID:

There are few options for patients whose cancers have metastasized due to resistance to current therapies. This team is using gene editing technology to modify a patient’s own immune system cells and blood-forming stem cells with the aim of creating a continuous supply of immune cells that can recognize and attack hard-to-treat cancers.


Single dose. 


Primary: Safety and feasibility. Secondary: Persistence of gene-marked anti-cancer immune cells